Drug Trial Radar · NCT00487994
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia
Last checked: Nov 19, 2026Latest source record: May 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,130
Actual
Start
Nov 2004
Primary completion
May 2007
Study completion May 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the overall safety of Lapaquistat Acetate, once daily (QD), by itself or in combination with atorvastatin in subjects with primary dyslipidemia.
Conditions
- Dyslipidemia
Interventions
Lapaquistat acetateDrug
Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
Lapaquistat acetate and atorvastatinDrug
Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
AtorvastatinDrug
Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lens Opacity Classification System findingsTime frame: Weeks 24, 48, 72, and 96 or Final Visit
- Best corrected visual acuityTime frame: Weeks 24, 48, 72, and 96 or Final Visit
- Adverse EventsTime frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96 or Final Visit
- Clinical Laboratory TestsTime frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96 or Final Visit
- Vital signs (blood pressure and pulse rate) and weightTime frame: Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96 or Final Visit
- 12-lead ElectrocardiogramTime frame: Weeks 48 and 96 or Final Visit
- Physical ExaminationTime frame: Weeks 48 and 96 or Final Visit
Locations
128 sites in 17 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Northport, Alabama
Site not named
Chandler, Arizona
Site not named
Phoenix, Arizona
Site not named
Sierra Vista, Arizona
Site not named
Jonesboro, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Rancho Cucamonga, California
Site not named
Santa Rosa, California
Site not named
Golden, Colorado
Site not named
Coral Gables, Florida
Site not named
Fort Myers, Florida
Site not named
Jacksonville, Florida
Site not named
Sarasota, Florida
Site not named
West Palm Beach, Florida
Site not named
Dunwoody, Georgia
Site not named
Boise, Idaho
Site not named
Idaho Falls, Idaho
Site not named
Arlington Heights, Illinois
Site not named
Chicago, Illinois
Site not named
Elk Grove Village, Illinois
Site not named
Evansville, Indiana
Site not named
Indianapolis, Indiana
Site not named
Waterloo, Iowa
Site not named
Kansas City, Kansas
Site not named
Overland Park, Kansas
Site not named
Louisville, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Flint, Michigan
Site not named
Edina, Minnesota
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Ship Bottom, New Jersey
Site not named
Rochester, New York
Site not named
Syracuse, New York
Site not named
Charlotte, North Carolina
Site not named
Statesville, North Carolina
Site not named
Wilmington, North Carolina
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.